Dr. Reddy’s Laboratories: Realizing an ambitious vision
This case describes the challenges that Dr. Reddy’s Laboratories, the second largest pharmaceutical company in India in 2009, faced in making its vision (of becoming the first discovery-led global pharmaceutical company from India – “the Merck or Pfizer of India”) a reality. The company had grown from its very humble beginnings to become a $1.4 billion multinational in the space of 25 short years. Dr. Reddy’s early success was based on unbranded and branded generics. The company had a global presence and India revenues represented only 16% of the total. Dr. Reddy’s had built a world class manufacturing organization and was also expert at mounting patent challenges. Through a series of acquisitions, the company had assembled a high quality global supply chain. As the generics opportunity began to plateau, Dr. Reddy’s has recently sought to develop its skills in new drug discovery and marketing. The company has launched four new growth businesses: (1) the polypill project that seeks to combine proven generics in a single pill to provide more effective and low cost treatments for chronic diseases like cardiovascular disease (CVD), depression and osteoarthritis; (2) a specialty dermatology business in the US; (3) high-margin (and high-risk) drug discovery, with five New Chemical Entities in the pipeline as of 2009; and (4) biologics, an exciting and fast-growing segment of the pharmaceuticals industry. The challenge for the student is to analyze how these dots are connected and whether these initiatives are sufficient for the company to realize its ambitious vision. The case also discusses how the company’s CEO, GV Prasad, has restructured the organization to help realize its vision and has sought to attract and retain the new kind of talent that would be needed in this effort.
The case is a good vehicle to discuss the changing landscape of the global pharmaceuticals industry. It is also useful for discussing the strategies of emerging global contenders from BRIC countries. Third, the case presents a rich backdrop for discussing how companies should manage the risks involved in corporate renewal. Should Dr. Reddy’s focus on what it is good at, i.e. generics and related products and services; or should it venture into the higher-margin but higher-risk discovery-led business? How can it do both?
2003 - 2009
IMD retains all proprietary interests in its case studies and notes. Without prior written permission, IMD cases and notes may not be reproduced, used, translated, included in books or other publications, distributed in any form or by any means, stored in a database or in other retrieval systems. For additional copyright information related to case studies, please contact Case Services.
Research Information & Knowledge Hub for additional information on IMD publications
The case study examines recent aviation safety concerns at Boeing, focusing on manufacturing issues, leadership decisions and regulatory oversight....
The case is seen through the eyes of the newly appointed supply chain director at a cosmetics company based in Berlin. The general manager has task...
Few Business to Business (B2B) marketplaces have succeeded. Metalshub has successfully combined a software platform as a service, with a marketplac...
The case focuses on Contabilizei, a Brazilian startup providing online accounting services for small and medium-sized enterprises (SMEs). The case ...
Companies that modularize and externalize their best capabilities are in a strong position to seize unexpected opportunities. Prediction is hard. T...
Leading Chinese companies are preparing to take advantage of exposure and opportunities as top sponsors and suppliers to the UEFA EURO 2024 Men’s S...
Research Information & Knowledge Hub for additional information on IMD publications
in I by IMD 24 June 2024
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-7-2457 ©2024
Research Information & Knowledge Hub for additional information on IMD publications
Case reference: IMD-7-2546 ©2024
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications
in MIT Sloan Management Review Summer 2024, vol. 65, no. 4
Research Information & Knowledge Hub for additional information on IMD publications
Research Information & Knowledge Hub for additional information on IMD publications